^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Alkylating agent

    Related drugs:
    15h
    A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Juventas Cell Therapy Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    19h
    A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bendamustine • melphalan
    2d
    GVHD-PTCy: Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Milton S. Hershey Medical Center | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    cyclophosphamide
    2d
    Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response. (PubMed, Invest Ophthalmol Vis Sci)
    MCM6 acts as a critical regulator of retinoblastoma growth and modulates response to melphalan. Targeting MCM6 may offer a therapeutic approach to improve outcomes of chemotherapy in retinoblastoma.
    Journal
    |
    MCM6 (Minichromosome Maintenance Complex Component 6)
    |
    melphalan
    3d
    Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. (PubMed, Front Immunol)
    This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide • tofacitinib
    3d
    Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics (clinicaltrials.gov)
    P1, N=36, Recruiting, medac GmbH | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    fludarabine IV • Grafapex (treosulfan)
    3d
    Modified Conditioning Regimen for CML-BP (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    melphalan • fludarabine IV • thiotepa
    3d
    Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov)
    P2, N=60, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • etoposide IV • idarubicin hydrochloride • Proleukin (aldesleukin) • busulfan • Neupogen (filgrastim)
    3d
    Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan University
    New P2 trial
    |
    albumin-bound paclitaxel • etoposide IV • irinotecan • Zepzelca (lurbinectedin)
    3d
    Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes. (PubMed, Pharmacogenomics)
    AA genotype at G681A in low BMI patients showed the poorest chemotherapy response and lowest PFS (HR>1). CYP2C19 variants (AA) may serve as predictive markers for non-responsiveness towards AC-T chemotherapy in low BMI BC patients, highlighting the need for genetic counselling and nutritional support to improve treatment outcomes.
    Journal
    |
    CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    cyclophosphamide
    4d
    SEEK: Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease (clinicaltrials.gov)
    P1, N=36, Recruiting, The Children's Hospital of Zhejiang University School of Medicine | N=72 --> 36
    Enrollment change
    |
    cyclophosphamide • fludarabine IV
    4d
    PROTraSarc: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients (clinicaltrials.gov)
    P=N/A, N=7, Terminated, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed --> Terminated; The study was terminated prematurely due to slow recruitment after inclusion of 7 patients (of initially planned 100 patients).
    Trial termination
    |
    Yondelis (trabectedin)